Tempest Therapeutics, Inc. Noncash or Part Noncash Acquisition, Fixed Assets Acquired
Tempest Therapeutics, Inc. (TPST) reported Noncash or Part Noncash Acquisition, Fixed Assets Acquired of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1 · last filed 2026-03-30
- Tempest Therapeutics, Inc. noncash or part noncash acquisition, fixed assets acquired for the quarter ending 2023-12-31 was -$3.00K, a 103.37% decline year-over-year.
- Tempest Therapeutics, Inc. noncash or part noncash acquisition, fixed assets acquired for the quarter ending 2022-12-31 was $89.00K, a 14.10% increase year-over-year.
- Tempest Therapeutics, Inc. noncash or part noncash acquisition, fixed assets acquired for the quarter ending 2022-09-30 was $0.00.
- Tempest Therapeutics, Inc. noncash or part noncash acquisition, fixed assets acquired for the quarter ending 2022-06-30 was -$12.00K.
- Tempest Therapeutics, Inc. noncash or part noncash acquisition, fixed assets acquired for fiscal 2025 was $0.00.
- Tempest Therapeutics, Inc. noncash or part noncash acquisition, fixed assets acquired for fiscal 2024 was $0.00.
- Tempest Therapeutics, Inc. noncash or part noncash acquisition, fixed assets acquired for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Tempest Therapeutics, Inc. noncash or part noncash acquisition, fixed assets acquired for fiscal 2022 was $93.00K, a 19.23% increase from fiscal 2021.
| Period end | Noncash or Part Noncash Acquisition, Fixed Assets Acquired 3 month | Noncash or Part Noncash Acquisition, Fixed Assets Acquired 6 month | Noncash or Part Noncash Acquisition, Fixed Assets Acquired 9 month | Noncash or Part Noncash Acquisition, Fixed Assets Acquired 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-30 | |||
| 2024-12-31 | $0.00 10-K · filed 2026-03-30 | |||
| 2023-12-31 | -$3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $0.00 10-K · filed 2025-03-27 | ||
| 2023-09-30 | $3.00K 10-Q · filed 2024-11-12 | |||
| 2022-12-31 | $89.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $89.00K derived: sum of 2 quarters · filed 2024-03-19 | $77.00K derived: sum of 3 quarters · filed 2024-03-19 | $93.00K 10-K · filed 2024-03-19 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$12.00K derived: sum of 2 quarters · filed 2023-11-08 | $4.00K 10-Q · filed 2023-11-08 | $82.00K derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | -$12.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $4.00K 10-Q · filed 2023-08-10 | $82.00K derived: sum of 3 quarters · filed 2023-08-10 | $82.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $16.00K 10-Q · filed 2023-05-10 | $94.00K derived: sum of 2 quarters · filed 2023-05-10 | $94.00K derived: sum of 3 quarters · filed 2023-05-10 | $94.00K derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $78.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $78.00K derived: sum of 2 quarters · filed 2023-03-22 | $78.00K derived: sum of 3 quarters · filed 2023-03-22 | $78.00K 10-K · filed 2023-03-22 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $0.00 derived: sum of 2 quarters · filed 2022-11-08 | $0.00 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $0.00 10-Q · filed 2022-08-15 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-13 | |||
| 2020-12-31 | $0.00 10-K · filed 2022-03-29 | |||
| 2017-12-31 | $25.00K 10-K · filed 2018-03-15 | |||
| 2016-12-31 | $55.00K 10-K · filed 2018-03-15 | |||
| 2015-12-31 | $1.00M 10-K · filed 2018-03-15 | |||
| 2014-12-31 | $133.00K 10-K · filed 2017-03-02 | |||
| 2013-12-31 | $0.00 10-K · filed 2016-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B |